Interferon beta-1a - Faron Pharmaceuticals

Drug Profile

Interferon beta-1a - Faron Pharmaceuticals

Alternative Names: FP-1201; FP-1201-lyo; MR11A8; Recombinant human interferon beta-1a - Faron Pharmaceuticals; Traumakine

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Faron Pharmaceuticals
  • Developer Faron Pharmaceuticals; Maruishi Pharmaceutical
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult respiratory distress syndrome; Acute lung injury
  • New Molecular Entity No

Highest Development Phases

  • Phase III Adult respiratory distress syndrome
  • Phase II Abdominal aortic aneurysm; Acute lung injury
  • Discontinued Brain injuries; Spinal cord injuries

Most Recent Events

  • 11 Dec 2017 Faron Pharmaceuticals completes enrolment in the INTEREST trial for Adult respiratory distress syndrome in Finland, Germany, Spain, Czech Republic, Belgium, France, Italy and United Kingdom
  • 01 Dec 2017 Faron Pharmaceuticals announces intention to submit MAA to EMA for Adult respiratory distress syndrome
  • 06 Sep 2017 Faron Pharmaceuticals files for patent protection with the United States Patent and Trademark Office and The Patent Cooperation Treaty for interferon-beta before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top